克唑替尼治疗肺癌的疗效及其耐药后的治疗

doi:10.3760/cma.j.issn.1673422X.2016.07.013

摘要/Abstract

摘要： 以棘皮动物微管相关蛋白4间变性淋巴瘤激酶(EML4ALK)融合基因突变为靶点的酪氨酸激酶抑制剂(TKI)克唑替尼能够显著延长晚期ALK阳性非小细胞肺癌（NSCLC）患者的无进展生存期（PFS)，一线、二线单药治疗的中位PFS分别为10.9个月和7.7个月。尽管克唑替尼的初始疗效良好，但大部分患者于治疗1年内出现耐药并显示疾病复发，其原因是ALK融合基因扩增和二次突变。临床试验证实二代ALK抑制剂、联合热休克蛋白等能有效克服克唑替尼耐药。

关键词: 肺肿瘤, 抗药性, 肿瘤, 治疗

Abstract: Crizotinib is a tyrosine kinase inhibitor (TKI), which is a target for echinoderm microtubule associated protein like 4anaplastic lymphoma kinase (EML4ALK). It can prolong the progression free survival (PFS) of ALK positive patients with advanced nonsmall cell lung cancer (NSCLC). The median PFS in the firstline and secondline mPFS is 10.9 months and 7.7 months. However, despite an initial benefit, patients inevitably experience tumor progression, due to the ALK fusion gene amplification and secondary mutations of ALK kinase domain. Clinical trials show the promising efficacy like next generation ALK inhibitors and heat shock protein 90 (HSP90) can overcome acquired resistance.

Key words: Lung neplasms, Drug resistance, neoplasm, Therapy

朱礼阳, 于忠和. 克唑替尼治疗肺癌的疗效及其耐药后的治疗[J]. 国际肿瘤学杂志, 2016, 43(7): 532-534.

ZHU Li-Yang, YU Zhong-He. Therapeutic effects of crizotinib in lung cancer and the treatment after drug resistance[J]. Journal of International Oncology, 2016, 43(7): 532-534.

参考文献

［1］ Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4ALK fusion gene in nonsmallcell lung cancer［J］. Nature, 2007, 448(7153): 561566. DOI: 10.1038/nature05945. ［2］ Shackelford RE, Vora M, Mayhall K, et al. ALKrearrangements and testing methods in nonsmall cell lung cancer: a review［J］. Genes Cancer, 2014, 5(1/2): 114. ［3］ Pan Y, Zhang Y, Li Y, et al. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion patternspecific clinicopathologic, histologic and cytologic features［J］. Lung Cancer, 2014, 84(2): 121126. DOI: 10.1016/j.lungcan.2014.02.007. ［4］董江萍. FDA批准克里唑替尼及其基因测试法治疗晚期非小细胞肺癌［J］. 药物评价研究, 2011, 34(5): 402. ［5］ Solomon BJ, Mok T, Kim DW, et al. Firstline crizotinib versus chemotherapy in ALKpositive lung cancer［J］. N Engl J Med, 2014, 371(23): 21672177. DOI: 10.1056/NEJMx150034. ［6］ Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALKpositive lung cancer［J］. N Engl J Med, 2013, 368(25): 23852394. DOI: 10.1056/NEJMoa1214886. ［7］ Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALKpositive nonsmallcell lung cancer: updated results from a phase 1 study［J］. Lancet Oncol, 2012, 13(10): 10111019. DOI: 10.1016/S14702045(12)703443. ［8］ Solomon BJ, Mok T, Kim DW, et al. Firstline crizotinib versus chemotherapy in ALKpositive lung cancer［J］. N Engl J Med, 2014, 371(23): 21672177. DOI: 10.1056/NEJMoa1408440. ［9］穆晶, 吴卫华, 蔡毅然, 等. ALK阳性并克唑替尼治疗有效肺鳞状细胞癌临床病理分析［J］. 临床和实验医学杂志, 2015 (11): 919922. DOI: 10.3969/j.issn.16714695.2015.011.018. ［10］ Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1rearranged nonsmallcell lung cancer［J］. N Engl J Med, 2014, 371(21): 19631971. DOI: 10.1056/NEJMoa1406766. ［11］ Heuckmann JM, BalkeWant H, Malchers F, et al. Differential protein stability and ALK inhibitor sensitivity of EML4ALK fusion variants［J］. Clin Cancer Res, 2012, 18(17): 46824690. DOI: 10.1158/10780432.CCR113260. ［12］ Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALKrearranged lung cancers［J］. Sci Transl Med, 2012, 4(120): 120ra17. DOI: 10.1126/scitranslmed.3003316. ［13］ Perez CA, Velez M, Raez LE, et al. Overcoming the resistance to crizotinib in patients with nonsmall cell lung cancer harboring EML4/ALK translocation［J］. Lung Cancer, 2014, 84(2): 110115. DOI: 10.1016/j.lungcan.2014.02.001. ［14］ Ou SH, Ahn JS, De Petris L, et al. Alectinib in Crizotinibrefractory ALKrearranged nonsmallcell lung cancer: a phase Ⅱ global study［J］. J Clin Oncol, 2016, 34(7): 661668. DOI: 10.1200/JCO.2015.63.9443. ［15］ Ou SH, Jnne PA, Bartlett CH, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALKpositive NSCLC［J］. Ann Oncol, 2014, 25(2): 415422. DOI: 10.1093/annonc/mdt572. ［16］ Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment［J］. Clin Cancer Res, 2010, 16(22): 55815590. DOI: 10.1158/10780432.CCR100851. ［17］ Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression［J］. Mol Cancer, 2010, 9: 188. DOI: 10.1186/147645989188. ［18］ Sang J, Acquaviva J, Friedland JC, et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in nonsmall cell lung cancer［J］. Cancer Discov, 2013, 3(4): 430443. DOI: 10.1158/21598290.CD120440. ［19］ Sessa C, Shapiro GI, Bhalla KN, et al. Firstinhuman phase Ⅰ doseescalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors［J］. Clin Cancer Res, 2013, 19(13): 36713680. DOI: 10.1158/10780432.CCR123404.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[3]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[4]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[5]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[6]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[7]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[8]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[9]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[10]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[11]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[12]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[13]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[14]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[15]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.